Friday, August 28, 2015

AstraZeneca to pay $520 million settlement in anti-psychotic drug case

AstraZeneca, the British drugmaker with its American headquarters in Wilmington, Del., has agreed to a $520 million civil settlement over allegations that it illegally marketed its antipsychotic drug Seroquel for uses that were not approved by the U.S. Food and Drug Administration.

AstraZeneca to pay $520 million settlement in anti-psychotic drug case

0 comments

AstraZeneca, the British drugmaker with its American headquarters in Wilmington, Del., has agreed to a $520 million civil settlement over allegations that it illegally marketed its antipsychotic drug Seroquel for uses that were not approved by the U.S. Food and Drug Administration.

U.S. Attorney General Eric Holder said, the civil penalty was the “largest amount ever paid by a company in a civil-only settlement of off-label marketing claims.”

The initial allegations were filed in a whistleblower lawsuit brought under the False Claims Act. It alleged that between January 2001 and December 2006, AstraZeneca marketed Seroquel to doctors for Altzheimer’s disease, anger management, aggression, anxiety, attention deficit hyperactivity disorder, bipolar maintenance, post-traumatic stress disorder and sleeplessness. Companies are not allowed to market drugs for so-called “off-label” uses, although doctors are allowed to prescribe drug for those conditions.

The case was pursued by the U.S Attorney’s Office for the Eastern District of Pennsylvania in , which announced the settlement.

More coverage
 
Please pass the chocolate I feel mood coming on
 
A potentially dangerous drug combo

“When pharmaceutical companies interfere with the FDA’s mission to insure that drugs are safe and effective, they … put the health and safety of patients at risk,” said U.S. Attorney Michael L. Levy in a statement. “People have a legal right to know that pharmaceutical companies are marketing their drugs only for uses approved by the FDA and that their doctors’ judgment has not been affected by misinformation from a pharmaceutical company trying to boost revenues.”

In a release, the company acknowledged that it had entered the settlement and that in addition to $520 million civil penalty that would be shared with state governments, the company would enter into a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services. As part of that agreement, AstraZeneca will post on its website information about payments it makes to doctors, including money for speeches, other honoraria, travel, and lodging expenses.

AstraZeneca also faces thousands of personal injury lawsuits from people who took the drug alleging that they were harmed by it. In March, the company won a defense verdict from a New Jersey jury in the first Seroquel case to go to trial.

Last month, Horsham Pa.-based Institute for Safe Medication Practices said that between July and September 2009, the FDA got nearly 1,000 reports of serious, disabling, or fatal events that were linked to this medicine. ISMP said that most of those report were patients who became diabetic while taking the drug. According to the reports sent to the FDA, patients on the drug, whose generic name is quetiapine, more often become diabetic than people with similar risks of the condition who take other medications.

In 2009, Seroquel generated $4.2 billion in U.S. sales, according to IMS Health, which tracks prescription drug sales. The drug ranked fifth in drug sales in the U.S., according to IMS which has a regional headquarters in Plymouth Meeting, Pa.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog

Check Up is a blog for savvy health consumers, covering the latest developments, discoveries, and debates from the Philadelphia area and beyond.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Charlotte Sutton Health and Science Editor, Philadelphia Inquirer
Tom Avril Inquirer Staff Writer, heart health and general science
Stacey Burling Inquirer Staff Writer, nueroscience and ageing
Marie McCullough Inquirer Staff Writer, cancer and women's health
Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Hooman Noorchashm, M.D., Ph.D. Cardiothoracic surgeon in the Philadelphia area
Amy J. Reed, M.D., Ph.D. Anesthesiologist and Surgical Intensivist in the Philadelphia Area
Latest Health Videos
Also on Philly.com:
letter icon Newsletter